Division of Hematology-Oncology, Children's Hospital of Zhejiang University School of Medicine, Hangzhou, PR China.
Leuk Res. 2013 Feb;37(2):134-8. doi: 10.1016/j.leukres.2012.11.002. Epub 2012 Nov 28.
Flow cytometry based minimal residual disease (MRD) was evaluated for outcome prediction in childhood acute myeloid leukemia (AML). The median levels of MRD in relapsed and nonrelapsed patients were different after the first induction (0.64% vs. 0.18%, P=0.030). A cutoff level of ≥ 0.25% after the first course of induction was correlated with a high risk of relapse in both univariate analysis (5-year cumulative incidence of relapse: 66.8% vs. 21.2%, P=0.002) and multivariate analyses (hazard ratio: 3.70, 95% CI, 1.23-11.08, P=0.020). Our results showed that MRD level after the first induction therapy provides important information for risk assessment in childhood AML.
基于流式细胞术的微小残留病（MRD）评估可预测儿童急性髓系白血病（AML）的预后。首次诱导后，复发和未复发患者的 MRD 中位数水平不同（0.64% vs. 0.18%，P=0.030）。首次诱导后≥0.25%的临界值与单因素分析（5 年累积复发率：66.8% vs. 21.2%，P=0.002）和多因素分析（危险比：3.70，95%CI，1.23-11.08，P=0.020）中的高复发风险相关。我们的结果表明，首次诱导治疗后 MRD 水平为儿童 AML 的风险评估提供了重要信息。
